Nab-paclitaxel: 1L trials
Nab-paclitaxel in patients with “aggressive disease” (poor prognostic factors)
O’Saughnessy et al BCRT 2013
•
Retrospective analysis from phase III (CA012) and phase II (Ca024) trials
•
Poor prognostic factors: DFI <2 yrs and visceral dominant mtx.
•
PFS and OS trends similar to ORR, only significant in
visceral dominant metastases in CA024 (13.1 mo for
NabP150 vs 7.8 mo for doce* and 7.5 mo for NabP100*)
•
Safety results similar to previous reports
CA012
Mean maximum % tumor shrinkage
